Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia

Bone Marrow Transplantation

Volumn 47, Issue 2, 2012, Pages 231-235

  Mahindra, A ^a   Bolwell, B J ^b   Rybicki, L ^c   Elder, P ^d   Kalaycio, M ^b   Dean, R ^b   Avalos, B ^d   Sobecks, R ^b   Tench, S ^b   Andresen, S ^b   Pohlman, B ^b   Sweetenham, J ^b   Devine, S ^d   Copelan, E ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

etoposide; lymphoma; priming; secondary malignancies

Indexed keywords

ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; APHERESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CD34 SELECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SECOND CANCER; STEM CELL MOBILIZATION; UNITED STATES;

EID: 84857035363     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.73     Document Type: Article

References (16)

1. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M et al. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol 1999; 17: 423-429. (Pubitemid 29022421)
2. Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006; 12: 1065-1072.
3. Wadehra N, Farag S, Bolwell B, Elder P, Penza S, Kalaycio M et al. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 1343-1349. (Pubitemid 44858268)
4. Copelan EA, Ceselski SK, Ezzone SA, Lasky LC, Penza SL, Bechtel TP et al. Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease. J Clin Oncol 1997; 15: 759-765. (Pubitemid 27074246)
5. Krishnan A, Bhatia S, Slovak ML, Arber DA, Niland JC, Nademanee A et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000; 95: 1588-1593. (Pubitemid 30120817)
6. Metayer C, Curtis RE, Vose J, Sobocinski KA, Horowitz MM, Bhatia S et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multi-center case-control study. Blood 2003; 101: 2015-2023. (Pubitemid 36237609)
7. Micallef IN, Lillington DM, Apostolidis J, Amess JA, Neat M, Matthews J et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000; 18: 947-955. (Pubitemid 30123769)
8. Darrington DL, Vose JM, Anderson JR, Bierman PJ, Bishop MR, Chan WC et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and auto-logous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994; 12: 2527-2534.
9. Hosing C, Munsell M, Yazji S, Andersson B, Couriel D, de Lima M et al. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol 2002; 13: 450-459. (Pubitemid 34705008)
10. Stone RM, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe SN et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 2535-2542. (Pubitemid 24379636)
11. Copelan E, Hoshaw-Woodard S, Elder P, Penza S, Farag S, Marcucci G et al. Therapy-related myelodysplasia and leukemia occur infrequently following VP-16 priming and autotransplantation without total body irradiation. Bone Marrow Transplant 2004; 34: 85-87. (Pubitemid 39022962)
12. Thirman MJ, Larson RA. Therapy-related myeloid leukemia. Hematol Oncol Clin North Am 1996; 10: 293-320. (Pubitemid 26097342)
13. Kalaycio M, Rybicki L, Pohlman B, Sobecks R, Andresen S, Kuczkowski E et al. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelo-dysplasia and acute myelogenous leukemia. J Clin Oncol 2006; 24: 3604-3610. (Pubitemid 46630533)
14. Gordan LN, Sugrue MW, Lynch JW, Williams KD, Khan SA, Wingard JR et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2003; 44: 815-820. (Pubitemid 36410987)
15. Bolwell BJ, Pohlman B, Rybicki L, Sobecks R, Dean R, Curtis J et al. Patients mobilizing large numbers of CD34+ cells ('super mobilizers') have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant 2007; 40: 437-441. (Pubitemid 47288222)
16. Yoon DH, Sohn BS, Jang G, Kim EK, Kang BW, Kim C et al. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma. Transfusion 2009; 49: 1890-1900.